| Molecular and cellular science and engineering efforts over the past decade have given rise to numerous novel approaches for treating disease. These approaches have substantial potential to provide highly specific and efficacious therapies for challenging disease targets (e.g. persistent pathogen infections, neurodegenerative disease and cancer). This session will highlight these creative approaches, including but not limited to combination drug therapies, novel drug delivery systems (e.g. mechanisms to cross the blood-brain barrier), catalytic (e.g. proteolytic) therapies, nanotherapies, nucleic acid and RNA interference therapies, gene therapies, oncolytic viruses, cell and stem cell based therapies. Both discovery and development efforts, including therapeutic design approaches based on systems-level modeling, will be covered. Furthermore, translation of these ‘next generation’ therapeutics for the treatment of specific disease targets will be emphasized. |
Promising Vaccine Adjuvants Based On Novel Amphiphilic Polyanhydrides
Maria P. Torres1, Jennifer Wilson2, Michael Wannemuehler3, Surya K. Mallapragada4 and Balaji Narasimhan1, (1)CBE, Iowa State University, 2114 Sweeney Hall, Ames, IA 50011, (2)Iowa State University, 2180 Vet Med, Ames, IA 50011-2250, (3)Veterinary Microbiology & Preventive Medicine, Iowa State University, 2180 Vet Med, Ames, IA 50011, (4)Chemical and Biological Engineering, Iowa State University, 2114 Sweeney Hall, Ames, IA 50011 |
Anti-HIV Rnai Targeting A Highly Conserved Viral Sequence Results In Novel Mechanisms Of Escape
Priya S. Shah, Chemical Engineering, University of California at Berkeley, 201 Gilman Hall, Berkeley, CA 94720, Joshua N. Leonard, Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bldg. 10 Rm. 4B36, Bethesda, MD 20892 and David V. Schaffer, University of California at Berkeley, Department of Chemical Engineering, 201 Gilman Hall, Berkeley, CA 94720-1462 |
Quantitative Characterization Of Defective Interfering Virus-Like Particles
Kristen Thompson, Chemical and Biological Engineering, University of Wisconsin-Madison, 1415 Engineering Drive, Madison, WI 53706-1607 and John Yin, Chemical and Biological Enginering, University of Wisconsin-Madison, 1415 Engineering Drive, Madison, WI 53706-1607 |
Targeted Gene Therapy of B-Cell Lymphoma by Engineered Retroviral Vectors
Haiguang Yang1, Leslie Bailey1, Yuning Lei1, Taehoon Cho1, Kye Il Joo1, Bingbing Dai1, Lili Yang2 and Pin Wang1, (1)The Mork Family Department of Chemical Engineering and Material Science, University of Southern California, 925 Bloom Walk, HED-216, Los Angeles, CA 90089-1211, (2)Division of Biology, California Institute of Technology, Pasadena, CA 91125 |
Impact Of Target Mrna Structure On Sirna Silencing Efficiency And Immune Stimulation In RNA Interference
Joseph A. Gredell1, Angela Berger1 and S. Patrick Walton2, (1)Department of Chemical Engineering and Materials Science, Michigan State University, 2527 Engineering Building, East Lansing, MI 48824, (2)Department of Chemical Engineering and Materials Science, Michigan State University, 3249 Engineering Building, East Lansing, MI 48823 |
In Vitro Studies Of Selective Targeting Of Pigmented Retinal Pigment Epithelial (Rpe) Cells And Subsequent Bio-Stimulation
Qing Song1, Ramon Risco Delgado2, Mark Latina3, Francosi Berthiaume1, Yaakov Nahmias1 and Martin Yarmush4, (1)Surgery, Massachusetts General Hospital, Harvard Medical School, 51 Blossom Street, Shriners Burns Hospital, Boston, MA 02114, (2)Fisica Aplicada III, Física Aplicada III, Escuela Tecnica Superior de Ingenieros, Universidad de Sevilla, Spain, Camino de los Descubrimientos s/n 41092 Seville, Spain, Seville, 41092, Spain, (3)Surgery, Massachusetts General Hospital, Harvard Medical School, 51 Blossom Street, Boston, MA 02114, (4)Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medial School, 51 Blossom Street, Boston, MA 02114 |
|